Anti-PD-1/PD-L1 Antibodies Combine with Chemotherapy or CTLA4 Antibodies for First-Line Treatment of Advanced Lung Cancer

被引：0
|
作者：
Fan, Y. [1 ]
Xu, X. [2 ]
机构：
[1] Zhejiang Canc Hosp, Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
lung cancer; Checkpoint inhibitors; chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.07-057
引用
收藏
页码：S2149 / S2150
页数：2
相关论文
共 50 条
  • [21] The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
    James Randall Patrinely
    Anna K. Dewan
    Douglas B. Johnson
    BioDrugs, 2020, 34 : 495 - 503
  • [22] Anti-PD1 antibodies plus chemotherapy for first-line treatment of advanced oesophageal squamous cell carcinoma
    Qian, J.
    Lin, W.
    Wang, H.
    Du, X.
    Wu, M.
    Huang, Y.
    Xu, N.
    Teng, L.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1749 - 1749
  • [23] The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer
    Ito, Kentaro
    Miura, Satoru
    Sakaguchi, Tadashi
    Murotani, Kenta
    Horita, Nobuyuki
    Akamatsu, Hiroaki
    Uemura, Kohei
    Morita, Satoshi
    Yamamoto, Nobuyuki
    LUNG CANCER, 2019, 128 : 113 - 119
  • [24] The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma
    Han, Fuxin
    Wu, Zhaozhen
    Chen, Jiaxin
    Liu, Meicen
    Hu, Yi
    CANCER MEDICINE, 2023, 12 (23): : 21129 - 21137
  • [25] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [26] Pharmacokinetic analysis of anti-PD-1 and PD-L1 antibodies and evaluation of their anti-tumor effects
    Hatakeyama, Hiroto
    Kurino, Taiki
    Matsuda, Reiko
    Suzuki, Hiroyuki
    Terui, Ayu
    Uehara, Tomoya
    Arano, Yasushi
    Hisaka, Akihiro
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies
    Borch, Troels H.
    Donia, Marco
    Andersen, Mads H.
    Svane, Inge M.
    DRUG DISCOVERY TODAY, 2015, 20 (09) : 1127 - 1134
  • [28] Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan
    Harada, Kentaro
    Yamamoto, Shun
    Kato, Ken
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (11) : 1333 - 1338
  • [29] Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects
    Li, Wenyu
    Gu, Junjie
    Fan, Hongwei
    Zhang, Li
    Guo, Jun
    Si, Lu
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 201
  • [30] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
    Masuda, Ken
    Horinouchi, Hidehito
    Tanaka, Midori
    Higashiyama, Ryoko
    Shinno, Yuki
    Sato, Jun
    Matsumoto, Yuji
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
12345